Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QMF149 versus mometasone furoate in asthma over 52 weeks
2015-002529-21Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of indacaterol and mometasone in asthma (5 arms), sponsored by Novartis. Primary endpoint: FEV1 superiority at 26 weeks. Started Sep 2015; status: completed.
02
Drugs
indacaterolmometasone
03
Conditions
asthma
Beyond the preview
Go deeper on 2015-002529-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002529-21.